The Current Ratio as of September 2024 (TTM) for ALX Oncology Holdings Inc. (ALXO) is 4.39

According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.39. This represents a change of -14.39% compared to the average of 5.13 of the last 4 quarters.

ALX Oncology Holdings Inc. (ALXO) Historical Current Ratio (quarterly & annually)

How has ALXO Current Ratio performed in the past?

The mean historical Current Ratio of ALX Oncology Holdings Inc. over the last ten years is 19.37. The current 4.39 Current Ratio has changed 2.17% with respect to the historical average. Over the past ten years (40 quarters), ALXO's Current Ratio was at its highest in in the December 2020 quarter at 69.99. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

ALX Oncology Holdings Inc. (ALXO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ALX Oncology Holdings Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ALX Oncology Holdings Inc. (ALXO) Average Current Ratio

How has ALXO Current Ratio performed in the past?

The current Current Ratio of ALX Oncology Holdings Inc. (ALXO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

ALX Oncology Holdings Inc. (ALXO) Current Ratio vs. Peers

How is ALXO’s Current Ratio compared to its peers?

ALX Oncology Holdings Inc.’s Current Ratio is less than Cabaletta Bio, Inc. (11.52), greater than Viracta Therapeutics, Inc. (1.08), less than EyePoint Pharmaceuticals, Inc. (4.75), less than Biomea Fusion, Inc. (4.62), less than Crinetics Pharmaceuticals, Inc. (16.09), greater than Immatics N.V. (3.74), greater than BioAtla, Inc. (3.81), less than Aerovate Therapeutics, Inc. (6.51), less than Dyne Therapeutics, Inc. (26.63), less than Edgewise Therapeutics, Inc. (30.24), less than Cullinan Oncology, Inc. (28.87), less than Stoke Therapeutics, Inc. (6.67), less than Mineralys Therapeutics, Inc. (11.20), less than Century Therapeutics, Inc. (10.62), less than C4 Therapeutics, Inc. (5.09), greater than TCR2 Therapeutics Inc. (2.96), less than Revolution Medicines, Inc. (15.42), less than Black Diamond Therapeutics, Inc. (6.87), greater than Atreca, Inc. (1.58), less than Passage Bio, Inc. (7.67),

Build a custom stock screener for ALX Oncology Holdings Inc. (ALXO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ALX Oncology Holdings Inc. (ALXO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.